India Biosimilars Market Size & Outlook, 2020-2027
India biosimilars market, 2016-2027 (US$M)
Related Markets
India biosimilars market highlights
- The India biosimilars market generated a revenue of USD 619.3 million in 2020 and is expected to reach USD 2,725.1 million by 2027.
- The India market is expected to grow at a CAGR of 23.6% from 2021 to 2027.
- In terms of segment, recombinant non-glycosylated proteins was the largest revenue generating product in 2020.
- Recombinant Glycosylated Proteins is the most lucrative product segment registering the fastest growth during the forecast period.
Biosimilars market data book summary
| Market revenue in 2020 | USD 619.3 million |
| Market revenue in 2027 | USD 2,725.1 million |
| Growth rate | 23.6% (CAGR from 2020 to 2027) |
| Largest segment | Recombinant non-glycosylated proteins |
| Fastest growing segment | Recombinant Glycosylated Proteins |
| Historical data | 2016 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins |
| Key market players worldwide | Amgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc |
Other key industry trends
- In terms of revenue, India accounted for 4.7% of the global biosimilars market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In Asia Pacific, China biosimilars market is projected to lead the regional market in terms of revenue in 2027.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,725.1 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimilars Market Scope
Biosimilars Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
India biosimilars market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilars market will help companies and investors design strategic landscapes.
Recombinant non-glycosylated proteins was the largest segment with a revenue share of 54.06% in 2020. Horizon Databook has segmented the India biosimilars market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2016 to 2027.
Increase in government initiatives is a major factor anticipated to propel India’s market over the forecast period. For instance, the National Biotechnology Regulatory Authority Bill is expected to streamline the approval process of biosimilars.
Currently, various companies seeking to market their biosimilars in the country have to seek approval from multiple government agencies, thereby increasing the time required to reach the market. Thus, a clear pathway is anticipated to reduce cost and complexity of the approval process.
Other growth factors include rise in cost of treatments due to the use of biologic drugs, which can result in increased adoption of affordable biosimilars. The market for biosimilars is expected to shift toward cardiac diseases, cancers, and diabetes, which have treatment options that include complex biotech drugs.
Reasons to subscribe to India biosimilars market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of India biosimilars market databook
-
Our clientele includes a mix of biosimilars market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India biosimilars market , including forecasts for subscribers. This country databook contains high-level insights into India biosimilars market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
India biosimilars market size, by product, 2016-2027 (US$M)
India Biosimilars Market Outlook Share, 2020 & 2027 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
